-DOCSTART- -X- O
Understanding -X- _ O
the -X- _ O
structural -X- _ O
organization -X- _ O
of -X- _ O
lipids -X- _ O
in -X- _ O
the -X- _ O
cell -X- _ O
and -X- _ O
viral -X- _ O
membranes -X- _ O
is -X- _ O
essential -X- _ O
for -X- _ O
elucidating -X- _ O
mechanisms -X- _ O
of -X- _ O
viral -X- _ O
fusion -X- _ O
that -X- _ O
lead -X- _ O
to -X- _ O
entry -X- _ O
of -X- _ O
enveloped -X- _ O
viruses -X- _ O
into -X- _ O
their -X- _ O
host -X- _ O
cells. -X- _ O
The -X- _ O
HIV -X- _ O
lipidome -X- _ O
shows -X- _ O
a -X- _ O
remarkable -X- _ O
enrichment -X- _ O
in -X- _ O
dihydrosphingomyelin -X- _ O
, -X- _ O
an -X- _ O
unusual -X- _ O
sphingolipid -X- _ O
formed -X- _ O
by -X- _ O
a -X- _ O
dihydrosphingosine -X- _ O
backbone. -X- _ O
Here -X- _ O
we -X- _ O
investigated -X- _ O
the -X- _ O
ability -X- _ O
of -X- _ O
dihydrosphingosine -X- _ B-Intervention
to -X- _ O
incorporate -X- _ O
into -X- _ O
the -X- _ O
site -X- _ O
of -X- _ O
membrane -X- _ O
fusion -X- _ O
mediated -X- _ O
by -X- _ O
the -X- _ O
HIV -X- _ O
envelope -X- _ O
( -X- _ O
Env -X- _ O
) -X- _ O
protein. -X- _ O
Dihydrosphingosine -X- _ B-Intervention
as -X- _ O
well -X- _ O
as -X- _ O
cholesterol -X- _ O
, -X- _ O
fatty -X- _ O
acid -X- _ O
, -X- _ O
and -X- _ O
tocopherol -X- _ O
was -X- _ O
conjugated -X- _ O
to -X- _ O
highly -X- _ O
conserved -X- _ O
, -X- _ O
short -X- _ O
HIV-1 -X- _ B-Patient
Env-derived -X- _ I-Patient
peptides -X- _ I-Patient
with -X- _ O
no -X- _ O
antiviral -X- _ O
activity -X- _ O
otherwise. -X- _ O
We -X- _ O
showed -X- _ O
that -X- _ O
dihydrosphingosine -X- _ B-Outcome
exclusively -X- _ I-Outcome
endowed -X- _ I-Outcome
nanomolar -X- _ I-Outcome
antiviral -X- _ I-Outcome
activity -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
peptides -X- _ I-Outcome
( -X- _ I-Outcome
IC -X- _ I-Outcome
( -X- _ I-Outcome
50 -X- _ I-Outcome
) -X- _ I-Outcome
as -X- _ I-Outcome
low -X- _ I-Outcome
as -X- _ I-Outcome
120 -X- _ I-Outcome
nM -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
HIV-1 -X- _ I-Outcome
infection -X- _ I-Outcome
on -X- _ I-Outcome
TZM-bl -X- _ I-Outcome
cells -X- _ I-Outcome
and -X- _ I-Outcome
on -X- _ I-Outcome
Jurkat -X- _ I-Outcome
T -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
cell-cell -X- _ I-Outcome
fusion -X- _ I-Outcome
assay. -X- _ I-Outcome
These -X- _ O
sphingopeptides -X- _ B-Outcome
were -X- _ I-Outcome
active -X- _ I-Outcome
against -X- _ I-Outcome
enfuvirtide- -X- _ I-Outcome
resistant -X- _ I-Outcome
and -X- _ I-Outcome
wild-type -X- _ I-Outcome
CXCR4 -X- _ I-Outcome
and -X- _ I-Outcome
CCR5 -X- _ I-Outcome
tropic -X- _ I-Outcome
HIV -X- _ I-Outcome
strains. -X- _ I-Outcome
The -X- _ O
anti-HIV -X- _ O
activity -X- _ O
was -X- _ O
determined -X- _ O
by -X- _ O
both -X- _ O
the -X- _ O
peptides -X- _ O
and -X- _ O
their -X- _ O
dihydrosphingosine -X- _ O
conjugate. -X- _ O
Moreover -X- _ O
, -X- _ O
their -X- _ B-Outcome
mode -X- _ I-Outcome
of -X- _ I-Outcome
action -X- _ I-Outcome
involved -X- _ I-Outcome
accumulation -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
cells -X- _ I-Outcome
and -X- _ I-Outcome
viruses -X- _ I-Outcome
and -X- _ I-Outcome
binding -X- _ I-Outcome
to -X- _ I-Outcome
membranes -X- _ I-Outcome
enriched -X- _ I-Outcome
in -X- _ I-Outcome
sphingomyelin -X- _ I-Outcome
and -X- _ I-Outcome
cholesterol. -X- _ I-Outcome
The -X- _ O
data -X- _ O
suggest -X- _ O
that -X- _ O
sphingopeptides -X- _ B-Outcome
are -X- _ I-Outcome
recruited -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
HIV -X- _ I-Outcome
membrane -X- _ I-Outcome
fusion -X- _ I-Outcome
site -X- _ I-Outcome
and -X- _ I-Outcome
provide -X- _ I-Outcome
a -X- _ I-Outcome
general -X- _ I-Outcome
concept -X- _ I-Outcome
in -X- _ I-Outcome
developing -X- _ I-Outcome
inhibitors -X- _ I-Outcome
of -X- _ I-Outcome
sphingolipid- -X- _ I-Outcome
mediated -X- _ I-Outcome
biological -X- _ I-Outcome
systems.â€”Ashkenazi -X- _ I-Outcome
, -X- _ O
A. -X- _ O
, -X- _ O
Viard -X- _ O
, -X- _ O
M. -X- _ O
, -X- _ O
Unger -X- _ O
, -X- _ O
L. -X- _ O
, -X- _ O
Blumenthal -X- _ O
, -X- _ O
R. -X- _ O
, -X- _ O
Shai -X- _ O
, -X- _ O
Y. -X- _ O
Sphingopeptides -X- _ B-Intervention
: -X- _ I-Intervention
dihydrosphingosine-based -X- _ I-Intervention
fusion -X- _ I-Intervention
inhibitors -X- _ I-Intervention
against -X- _ O
wild-type -X- _ B-Patient
and -X- _ I-Patient
enfuvirtide- -X- _ I-Patient
resistant -X- _ I-Patient
HIV-1 -X- _ I-Patient
. -X- _ O

